The TLR7/8 agonist R848 optimizes host and tumor immunity to improve therapeutic efficacy in murine lung cancer. Zhou J, Xu Y, Wang G, Mei T, et al. Int J Oncol 2022;61.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Zhou J, Xu Y, Wang G, Mei T, et al. The TLR7/8 agonist R848 optimizes host and tumor immunity to improve therapeutic efficacy in murine lung cancer. Int J Oncol 2022;61.
PMID: 35552764